Filamin-A expression in triple-negative breast cancer and its clinical significance

The quest for discovering novel biomarkers of triple-negative breast cancers (TNBCs) is ongoing. By lacking expression of hormonal receptors, this aggressive subtype of breast cancer presents a clinical dilemma with early recurrence, metastases and poor survival outcome. Filamin-A is a recent novel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Abderrahman Ouban
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	breast cancer tnbc biomarkers filamin-a prognosis Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/d97f3845d79b4b17a40e3ab3cb8c6794
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d97f3845d79b4b17a40e3ab3cb8c6794
record_format	dspace
spelling	oai:doaj.org-article:d97f3845d79b4b17a40e3ab3cb8c67942021-11-11T14:23:41ZFilamin-A expression in triple-negative breast cancer and its clinical significance1310-28181314-353010.1080/13102818.2021.1985611https://doaj.org/article/d97f3845d79b4b17a40e3ab3cb8c67942021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/13102818.2021.1985611https://doaj.org/toc/1310-2818https://doaj.org/toc/1314-3530The quest for discovering novel biomarkers of triple-negative breast cancers (TNBCs) is ongoing. By lacking expression of hormonal receptors, this aggressive subtype of breast cancer presents a clinical dilemma with early recurrence, metastases and poor survival outcome. Filamin-A is a recent novel protein which has proven to play a dual role as an oncogene and a tumour-suppressor in many malignancies. This study analysed the expression of Filamin-A in TNBC cases. Filamin-A was significantly expressed by the majority of the study’s sample, and was correlated with grade, clinical stage and TNM staging. Filamin-A is a versatile protein with numerous interactions with the cytoskeleton components of the tumour cell and with signalling proteins. Its role in modulating chemosensitivity to the chemotherapeutic agent Docetaxel is particularly important, especially in TNBC patients, who have few management options to choose from. This study provides evidence of the clinical significance of Filamin-A in TNBCs, and propose further functional studies to pinpoint the exact function of this protein in this difficult-to-treat subset of breast cancer patients.Abderrahman OubanTaylor & Francis Grouparticlebreast cancertnbcbiomarkersfilamin-aprognosisBiotechnologyTP248.13-248.65ENBiotechnology & Biotechnological Equipment, Vol 35, Iss 1, Pp 1409-1419 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer tnbc biomarkers filamin-a prognosis Biotechnology TP248.13-248.65
spellingShingle	breast cancer tnbc biomarkers filamin-a prognosis Biotechnology TP248.13-248.65 Abderrahman Ouban Filamin-A expression in triple-negative breast cancer and its clinical significance
description	The quest for discovering novel biomarkers of triple-negative breast cancers (TNBCs) is ongoing. By lacking expression of hormonal receptors, this aggressive subtype of breast cancer presents a clinical dilemma with early recurrence, metastases and poor survival outcome. Filamin-A is a recent novel protein which has proven to play a dual role as an oncogene and a tumour-suppressor in many malignancies. This study analysed the expression of Filamin-A in TNBC cases. Filamin-A was significantly expressed by the majority of the study’s sample, and was correlated with grade, clinical stage and TNM staging. Filamin-A is a versatile protein with numerous interactions with the cytoskeleton components of the tumour cell and with signalling proteins. Its role in modulating chemosensitivity to the chemotherapeutic agent Docetaxel is particularly important, especially in TNBC patients, who have few management options to choose from. This study provides evidence of the clinical significance of Filamin-A in TNBCs, and propose further functional studies to pinpoint the exact function of this protein in this difficult-to-treat subset of breast cancer patients.
format	article
author	Abderrahman Ouban
author_facet	Abderrahman Ouban
author_sort	Abderrahman Ouban
title	Filamin-A expression in triple-negative breast cancer and its clinical significance
title_short	Filamin-A expression in triple-negative breast cancer and its clinical significance
title_full	Filamin-A expression in triple-negative breast cancer and its clinical significance
title_fullStr	Filamin-A expression in triple-negative breast cancer and its clinical significance
title_full_unstemmed	Filamin-A expression in triple-negative breast cancer and its clinical significance
title_sort	filamin-a expression in triple-negative breast cancer and its clinical significance
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/d97f3845d79b4b17a40e3ab3cb8c6794
work_keys_str_mv	AT abderrahmanouban filaminaexpressionintriplenegativebreastcanceranditsclinicalsignificance
_version_	1718438992925425664

Filamin-A expression in triple-negative breast cancer and its clinical significance

Ejemplares similares